Vistagen Therapeutics is doubling down on its lead social anxiety candidate, even after the asset failed a phase 3 trial last December. | Vistagen Therapeutics is doubling down on its lead social ...

“Strategic transformations are a common and often successful approach in biotechnology,” Rami Levin, who took over as CEO of ...

A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way ...

BD has inked a technological partnership with automation provider Sinteco, aimed at pharmacy robotics. | The goal is to ...

Funding from the National Institutes of Health (NIH) generated $94.15 billion in economic activity and supported 390,863 jobs in 2025, according to a ...

In a strikingly blunt briefing, a senior FDA official accused uniQure of pushing “distorted” data to mask a “failed” therapy ...

Monoclonal antibodies have become one of the most established and clinically successful therapeutic modalities, supported by ...

Zealand Pharma’s Roche-partnered amylin analog demonstrated “placebo-like tolerability” and up to 10.7% mean weight loss at ...

Voyager Therapeutics has hit pause on a preclinical Alzheimer’s disease program just eight months after unveiling the asset. The neurology biotech announced back in July 2025 that it was adding a new ...

Bay Area laboratory solutions company Agilent Technologies has agreed to acquire Biocare Medical, a pathology solutions business, in an all-cash transaction valued at $950 million. | Bay Area ...

Roche is plugging 710 billion won (about $484 million) into South Korea’s biopharma industry, with the goal of attracting ...

LifeVac has picked up a groundbreaking clearance from the FDA for its suction-powered device designed to dislodge an object ...